As filed with the Securities and Exchange Commission on May 5, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Corvus Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware (State or other jurisdiction of incorporation or organization)
|
46-4670809 (I.R.S. Employer Identification Number)
|
863 Mitten Road, Suite 102
Burlingame, CA 94010
(650) 900-4520
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
2016 Equity Incentive Award Plan
(Full Title of the Plan)
Richard A. Miller, M.D.
President and Chief Executive Officer
Corvus Pharmaceuticals, Inc.
863 Mitten Road, Suite 102
Burlingame, CA 94010
(650) 900-4520
(Name, address, including zip code, and telephone number, including area code, of agent for service)
| Copies to: | ||
|
Phillip S. Stoup, Esq. Latham & Watkins LLP 140 Scott Drive Menlo Park, CA 94025 Telephone: (650) 328-4600 Facsimile: (650) 463-2600 | ||
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ¨ | Accelerated filer | ¨ | |||
| Non-accelerated filer | x | Smaller reporting company | x | |||
| Emerging growth company | ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
Proposed sale to take place as soon after the effective date of the
registration statement as awards under the plans are exercised and/or vest.
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,862,000 shares of the Registrant’s common stock issuable under the 2016 Equity Incentive Plan, for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-210456, 333-216590, 333-223622, 333-231331, 333-237933 and 333-255614) are effective, as a result of the operation of an automatic annual increase provision therein.
INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8
Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on March 29, 2016, March 10, 2017, March 13, 2018, May 9, 2019, April 30, 2020 and April 29, 2021 (File Nos. 333-210456, 333-216590, 333-223622, 333-231331, 333-237933 and 333-255614) are incorporated by reference herein.
Exhibit Index
#Indicates management contract or compensatory plan.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Burlingame, California, on this 5th day of May, 2022.
| Corvus Pharmaceuticals, Inc. | ||
| By: |
/s/ Richard A. Miller | |
| Richard A. Miller, M.D. | ||
| President and Chief Executive Officer | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Richard A. Miller, M.D. and Leiv Lea, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.
|
Signature |
Title |
Date | ||
|
/s/ Richard A. Miller Richard A. Miller M.D. |
President, Chief Executive Officer and Director (Principal Executive Officer) |
May 5, 2022 | ||
|
/s/ Leiv Lea Leiv Lea |
Chief Financial Officer (Principal Financial and Accounting Officer) |
May 5, 2022 | ||
|
/s/ Ian T. Clark Ian T. Clark |
Director | May 5, 2022 | ||
|
/s/ Elisha P. (Terry) Gould Elisha P. (Terry) Gould |
Director | May 5, 2022 | ||
|
/s/ Linda S. Grais, M.D., J.D. Linda S. Grais, M.D., J.D. |
Director | May 5, 2022 | ||
|
/s/ Scott W. Morrison Scott W. Morrison |
Director | May 5, 2022 | ||
|
/s/ Peter Thompson, M.D. Peter Thompson, M.D. |
Director | May 5, 2022 | ||
|
/s/ Edith P. Mitchell, M.D. Edith P. Mitchell, M.D. |
Director | May 5, 2022 |
Exhibit 5.1
| 140 Scott Drive | ||
| Menlo Park, California 94025 | ||
| Tel: +1.650.328.4600 Fax: +1.650.463.2600 | ||
| www.lw.com | ||
| FIRM / AFFILIATE OFFICES | ||
 |
Austin | Moscow |
| Beijing | Munich | |
| Boston | New York | |
| Brussels | Orange County | |
| Century City | Paris | |
| Chicago | Riyadh | |
| Dubai | San Diego | |
| Düsseldorf | San Francisco | |
| Frankfurt | Seoul | |
| Hamburg | Shanghai | |
| Hong Kong | Silicon Valley | |
| Houston | Singapore | |
| London | Tel Aviv | |
| Los Angeles | Tokyo | |
| Madrid | Washington, D.C. | |
| Milan | ||
May 5, 2022
Corvus Pharmaceuticals, Inc.
863 Mitten Road, Suite 102
Burlingame, CA 94010
| Re: | Registration Statement on Form S-8; 1,862,000 shares of Common Stock of Corvus Pharmaceuticals, Inc., par value $0.0001 per share |
Ladies and Gentlemen:
We have acted as special counsel to Corvus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the registration by the Company of an aggregate of 1,862,000 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) (the “Shares”) issuable under the 2016 Equity Incentive Award Plan (the “Plan”).
The Shares are included in a registration statement on Form S–8 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on May 5, 2022 (the “Registration Statement”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the prospectus forming a part thereof, other than as expressly stated herein with respect to the issuance of the Shares.
As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.
May 5, 2022
Page 2
Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Plan, assuming in each case that the individual issuances, grants or awards under the Plan are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the Plan (and the agreements and awards duly adopted thereunder and in accordance therewith), the issuance and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.
This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.
| Very truly yours, | |
| /s/ Latham & Watkins LLP |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Corvus Pharmaceuticals, Inc. of our report dated March 10, 2022 relating to the financial statements, which appears in Corvus Pharmaceuticals, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2021.
/s/ PricewaterhouseCoopers LLP
San Jose, California
May 5, 2022
1
Exhibit 107.1
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Corvus Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1—Newly Registered Securities
| Security
Type | Security
Class Title | Fee
Calculation Rule | Amount to be Registered(1) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration | |||||||||||||||||
| Equity | Common stock, $0.0001 par value per share | Rule 457(c) and Rule 457(h) | 1,862,000 | (2) | $ | 1.33 | (3) | $ | 2,476,460.00 | $ | 0.0000927 | $ | 229.57 | |||||||||||
| Total Offering Amounts | $ | 2,476,460.00 | $ | 229.57 | ||||||||||||||||||||
| Total Fee Offsets(4) | $ | — | ||||||||||||||||||||||
| Net Fee Due | $ | 229.57 | ||||||||||||||||||||||
(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of Corvus Pharmaceuticals, Inc.’s (the “Registrant”) common stock that become issuable under the 2016 Equity Incentive Award Plan (the “2016 Plan”) by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number of outstanding shares of common stock.
(2) Represents the additional shares of common stock available for future issuance under the Registrant’s 2016 Plan resulting from an annual increase as of January 1, 2022.
(3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price for shares reserved for future issuance under the 2016 Plan are based on the average of the high and the low price of Registrant’s Common Stock as reported on the Nasdaq Global Market on May 2, 2022, which was $1.33.
(4) The Registrant does not have any fee offsets.